At this time was present the new method the handling of the patient of heart cancer. These efforts were believed in could increase hope of his life.
The patient of heart cancer who was treated with sorafenib experienced the improvement on the life expectancy of 44%. Tea of New England Journal of Medicine published results of the third phase research, the tablet Sorafenib could reduce the risk of the death of 31% apda the patient with cancer of the heart cell stadum continued. Therefore, sorafenib was agreed for HCC medical treatment to by European Agency for the Evaluation of Medicinal Products (EMEA) from U.S. Food and Drug Administration (FDA) to Okteber and in November 2007.
“At this time the handling for other cancer had the handling that more advanced, was different from heart cancer that still experienced kesulitan,” said Dr. Josep M. Llovet, the representative of the head investigator and the professor from Barcelona Clinik Leiver Cancer (BCLC) Group IDIBAPS, Unit Liver, The Clinic hospital Barcelona in Jakarta. this happened because of the shortage of the medical treatment system to extend the life expectancy and the shortage of the opportunity to carry out the operation. “Medicine this became the first choice in the handling of heart cancer,” Josep words. According to him, the subject from this research reflected the new standard of the handling of heart cancer with the use Sorafenib.
”Globally the death rate in heart cancer continued to rise, was caused prevelensi the infection from B hepatitis and C,” Jordi Bruix words, Co-Principal investigator and the director from Barcelona Clinic Liver Cancer (BCLC) Group; the senior consultant, the Liver Unit, the hospital Barcelona.
The international SHARP research the third phase (Sorafenib HCC Assessment Randomizes Protokol) was carried out against 602 patients of heart cancer who did not yet get the handling beforehand. The research was carried out by comparing the level of continuation of the life on the whole, development time of the tumour, development time simptomatik between the patient that received sorafenib compared with plasebo. concerning results of this research was presented in American Society of Clinical Oncology in June 2007. in general the life expectancy figure of the patient that got sorafenib was 10.7 months.
whereas for the group that got plasebo only 7.9 months (HR=0,69; p=0,0006). Whereas in general time of the tumour expansion was 5.5 months with sorafenib compared with plasebo that is 2.8 months (HR=0,58;p= HR=0,58;p=<0,001).
The side-effect that was connected with medicine most often with the stage 3 or 4 that received Nexavar was diarrhoea and the reaction hand-foot-skin. There was no indication not balanced if seeing the serious side-effect between the Nexavar group and placebo. ”cancer the heart cell was the second type from cancer where Sorafenib showed the useful profit in a klinis,” manner said Dimitris Voliotis, MD, vice the president, Nexavar Clinical Development, Bayer Healthcare Pharmaceticals. ”We happy that at this time Sorafenib was available for the patient who contracted cancer and we will continue to work with the bodies of the world regulation to get use permission Sorafenib,” said Dimitris. (LID)